{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:15:39Z","timestamp":1722888939891},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00277-024-05840-7","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T09:02:14Z","timestamp":1718614934000},"page":"2845-2851","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?"],"prefix":"10.1007","volume":"103","author":[{"given":"E. U.","family":"Su\u00e1rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Boluda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Lavilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tormo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Botella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Vives","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Sayas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mart\u00ednez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Algarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Bergua-Burgues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Noriega-Concepci\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Raposo-Puglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Barrag\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Mart\u00ednez-Cuadr\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. L.","family":"Amigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"L\u00f3pez-Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"L\u00e1zaro-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. E.","family":"Guimaraes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Colorado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Garc\u00eda-Boyero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"De Rueda-Ciller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Foncillas-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Labrador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Alonso-Dominguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the PETHEMA group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"issue":"3","key":"5840_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM (2023) Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98(3):502\u2013526. https:\/\/doi.org\/10.1002\/ajh.26822","journal-title":"Am J Hematol"},{"issue":"23","key":"5840_CR2","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209\u20132221","journal-title":"N Engl J Med"},{"key":"5840_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-1-4939-6703-2_19","volume":"1541","author":"JJ Yang","year":"2017","unstructured":"Yang JJ, Park TS, Wan TS (2017) Recurrent cytogenetic abnormalities in acute myeloid leukemia. Methods Mol Biol 1541:223\u2013245","journal-title":"Methods Mol Biol"},{"issue":"12","key":"5840_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373(12):1136\u20131152","journal-title":"N Engl J Med"},{"issue":"12","key":"5840_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"issue":"5","key":"5840_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/blood.2020008211","volume":"137","author":"B Falini","year":"2021","unstructured":"Falini B, Brunetti L, Martelli MP (2021) How I diagnose and treat NPM1-mutated AML. Blood 137(5):589\u2013599","journal-title":"Blood"},{"issue":"9","key":"5840_CR7","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","volume":"35","author":"L Bullinger","year":"2017","unstructured":"Bullinger L, D\u00f6hner K, D\u00f6hner H (2017) Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. J Clin Oncol 35(9):934\u2013946. https:\/\/doi.org\/10.1200\/JCO.2016.71.2208","journal-title":"J Clin Oncol"},{"issue":"1","key":"5840_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41408-023-00835-5","volume":"13","author":"C Sargas","year":"2023","unstructured":"Sargas C, Ayala R, Larr\u00e1yoz MJ, Chill\u00f3n MC, Rodriguez-Arboli E, Bilbao C et al (2023) Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Blood Cancer J 13(1):77. https:\/\/doi.org\/10.1038\/s41408-023-00835-5","journal-title":"Blood Cancer J"},{"issue":"7","key":"5840_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"issue":"3","key":"5840_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126(3):291\u2013299. https:\/\/doi.org\/10.1182\/blood-2015-01-621664","journal-title":"Blood"},{"key":"5840_CR11","doi-asserted-by":"publisher","unstructured":"Vives S, Mart\u00ednez-Cuadr\u00f3n D, Bergua Burgues J, Algarra L, Tormo M, Mart\u00ednez-S\u00e1nchez MP; PETHEMA Group et al (2021) A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. Cancer 127(12):2003\u20132014. https:\/\/doi.org\/10.1002\/cncr.33403","DOI":"10.1002\/cncr.33403"},{"issue":"11","key":"5840_CR12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135(11):791\u2013803. https:\/\/doi.org\/10.1182\/blood.2019003988","journal-title":"Blood"},{"issue":"12","key":"5840_CR13","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/blood.v99.12.4326","volume":"99","author":"C Thiede","year":"2002","unstructured":"Thiede C, Steudel C, Mohr B, Schaich M, Sch\u00e4kel U, Platzbecker U et al (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99(12):4326\u20134335. https:\/\/doi.org\/10.1182\/blood.v99.12.4326","journal-title":"Blood"},{"issue":"45","key":"5840_CR14","doi-asserted-by":"publisher","first-page":"27882","DOI":"10.18632\/oncotarget.25328","volume":"9","author":"A Kuendgen","year":"2018","unstructured":"Kuendgen A, M\u00fcller-Thomas C, Lauseker M, Haferlach T, Urbaniak P, Schroeder T et al (2018) Efficacy of azacitidine is independent of molecular and clinical characteristics \u2013 an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature. Oncotarget 9(45):27882\u201327894. https:\/\/doi.org\/10.18632\/oncotarget.25328","journal-title":"Oncotarget"},{"issue":"6","key":"5840_CR15","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/bloodadvances.2019001335","volume":"4","author":"G Juliusson","year":"2020","unstructured":"Juliusson G, J\u00e4dersten M, Deneberg S, Lehmann S, M\u00f6llg\u00e5rd L, Wennstr\u00f6m L et al (2020) The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. Blood Adv 4(6):1094\u20131101","journal-title":"Blood Adv"},{"issue":"10","key":"5840_CR16","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1182\/blood-2017-09-807438","volume":"131","author":"J Straube","year":"2018","unstructured":"Straube J, Ling VY, Hill GR, Lane SW (2018) The impact of age, NPM1mut, and FLT3ITD allelic ratio in patients with acute myeloid leukemia. Blood 131(10):1148\u20131153. https:\/\/doi.org\/10.1182\/blood-2017-09-807438","journal-title":"Blood"},{"issue":"10","key":"5840_CR17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2014.58.0571","volume":"33","author":"F Ostronoff","year":"2015","unstructured":"Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A et al (2015) Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute\/Medical Research Council report. J Clin Oncol 33(10):1157\u20131164. https:\/\/doi.org\/10.1200\/JCO.2014.58.0571","journal-title":"J Clin Oncol"},{"key":"5840_CR18","doi-asserted-by":"publisher","unstructured":"Sargas C, Ayala R, Larr\u00e1yoz MJ, Chill\u00f3n MC, Rodriguez-Arboli E; PETHEMA cooperative study group et al (2023) Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Blood Cancer J 13(1):77. https:\/\/doi.org\/10.1038\/s41408-023-00835-5.","DOI":"10.1038\/s41408-023-00835-5"},{"issue":"23","key":"5840_CR19","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.3390\/cancers14235799","volume":"14","author":"R Ayala","year":"2022","unstructured":"Ayala R, Carre\u00f1o-Tarragona G, Barrag\u00e1n E, Boluda B, Larr\u00e1yoz MJ et al (2022) Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study. Cancers (Basel) 14(23):5799. https:\/\/doi.org\/10.3390\/cancers14235799","journal-title":"Cancers (Basel)"},{"issue":"9","key":"5840_CR20","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3390\/cancers14092342","volume":"14","author":"J Labrador","year":"2022","unstructured":"Labrador J, Mart\u00ednez-Cuadr\u00f3n D, de la Fuente A, Rodr\u00edguez-Veiga R, Serrano J, Tormo M et al (2022) Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry. Cancers (Basel) 14(9):2342. https:\/\/doi.org\/10.3390\/cancers14092342","journal-title":"Cancers (Basel)"},{"key":"5840_CR21","doi-asserted-by":"publisher","DOI":"10.1159\/000535628","author":"J DiGennaro","year":"2023","unstructured":"DiGennaro J, Sallman DA (2023) TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines. Therapies and Future Considerations Acta Haematol. https:\/\/doi.org\/10.1159\/000535628","journal-title":"Therapies and Future Considerations Acta Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05840-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05840-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05840-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T06:09:15Z","timestamp":1722060555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05840-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5840"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05840-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"assertion":[{"value":"15 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}